JP2019501882A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501882A5
JP2019501882A5 JP2018528340A JP2018528340A JP2019501882A5 JP 2019501882 A5 JP2019501882 A5 JP 2019501882A5 JP 2018528340 A JP2018528340 A JP 2018528340A JP 2018528340 A JP2018528340 A JP 2018528340A JP 2019501882 A5 JP2019501882 A5 JP 2019501882A5
Authority
JP
Japan
Prior art keywords
peptide
seq
derived
beclin
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018528340A
Other languages
English (en)
Japanese (ja)
Other versions
JP7350485B2 (ja
JP2019501882A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/079304 external-priority patent/WO2017093330A1/en
Publication of JP2019501882A publication Critical patent/JP2019501882A/ja
Publication of JP2019501882A5 publication Critical patent/JP2019501882A5/ja
Priority to JP2021162777A priority Critical patent/JP2022002530A/ja
Application granted granted Critical
Publication of JP7350485B2 publication Critical patent/JP7350485B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018528340A 2015-12-03 2016-11-30 ウイルスベクター効率を改善するための組成物及び方法 Active JP7350485B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021162777A JP2022002530A (ja) 2015-12-03 2021-10-01 ウイルスベクター効率を改善するための組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15306924 2015-12-03
EP15306924.0 2015-12-03
EP16194180.2 2016-10-17
EP16194180 2016-10-17
PCT/EP2016/079304 WO2017093330A1 (en) 2015-12-03 2016-11-30 Compositions and methods for improving viral vector efficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021162777A Division JP2022002530A (ja) 2015-12-03 2021-10-01 ウイルスベクター効率を改善するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2019501882A JP2019501882A (ja) 2019-01-24
JP2019501882A5 true JP2019501882A5 (enExample) 2019-10-24
JP7350485B2 JP7350485B2 (ja) 2023-09-26

Family

ID=57485463

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018528340A Active JP7350485B2 (ja) 2015-12-03 2016-11-30 ウイルスベクター効率を改善するための組成物及び方法
JP2021162777A Pending JP2022002530A (ja) 2015-12-03 2021-10-01 ウイルスベクター効率を改善するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021162777A Pending JP2022002530A (ja) 2015-12-03 2021-10-01 ウイルスベクター効率を改善するための組成物及び方法

Country Status (6)

Country Link
US (2) US11371061B2 (enExample)
EP (1) EP3383896A1 (enExample)
JP (2) JP7350485B2 (enExample)
CN (1) CN108699135B (enExample)
CA (1) CA3004971A1 (enExample)
WO (1) WO2017093330A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6175055B2 (ja) * 2011-06-30 2017-08-02 ジェネトン ウイルス感染増強特性を有するペプチドおよびその使用
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
CA3072461A1 (en) * 2017-08-10 2019-02-14 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of virus
CN107686523B (zh) * 2017-09-15 2021-05-14 山西大学 一种肿瘤酸度响应自噬诱导多肽及其制备方法和应用
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
US20220280602A1 (en) * 2019-07-31 2022-09-08 Lemonex Inc. Anticancer agent and method for preparation of porous silica particle
US20240025959A1 (en) * 2020-08-24 2024-01-25 University Of Southern California Beclin 2 and uses thereof for treating cancer and neurodegenerative diseases
EP4291666A4 (en) * 2021-02-15 2025-07-09 Biomarin Pharm Inc USE OF HISTIDINE-RICH PEPTIDES AS TRANSFECTION REAGENTS FOR THE PRODUCTION OF RAAV AND RBV
CN113713082B (zh) * 2021-08-27 2023-07-18 福建医科大学 一种用于阿尔茨海默症的纳米自噬诱导剂及其制备方法与应用
CN114316065B (zh) * 2021-10-29 2023-09-22 新乡医学院 小分子肽及其应用、细胞培养基、核酸分子
WO2024243639A1 (en) * 2023-05-31 2024-12-05 The Florey Institute Of Neuroscience And Mental Health Autophagy-inducing peptides
WO2025179154A1 (en) * 2024-02-21 2025-08-28 Vycellix, Inc. Compositions and methods for enhancing transduction efficiency of viral vectors with heparin and analogues thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
US20130202646A1 (en) * 2010-02-25 2013-08-08 San Diego State University (Sdsu) Foundation Compositions and methods for modulating autophagy
JP6175055B2 (ja) * 2011-06-30 2017-08-02 ジェネトン ウイルス感染増強特性を有するペプチドおよびその使用
EP2812347B1 (en) 2012-02-11 2016-08-24 Board Of Regents, The University Of Texas System Autophagy-inducing peptide
EP2943203A4 (en) * 2013-01-11 2016-08-24 Scripps Research Inst METHOD AND COMPOSITIONS FOR INCREASING THE TRANSDUCTION EFFICIENCY OF RETROVIRAL VECTORS
US20140271584A1 (en) 2013-03-15 2014-09-18 The Research Foundation For The State University Of New York Methods and Compositions for Direct Reprogramming of Somatic Cells to Stem Cells, and Uses of these Cells
EP3046571A4 (en) * 2013-09-18 2017-03-15 Ndsu Research Foundation COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH y-HERPESVIRUSES
WO2016119856A1 (en) * 2015-01-29 2016-08-04 Universite De Strasbourg Autophagy-inducing molecules for increasing insulin release
EP3141680B1 (en) * 2015-09-09 2018-01-31 U-Shin Italia S.p.A. Electronic handle for a vehicle door
EP3356397A1 (en) * 2015-09-28 2018-08-08 Fondazione Telethon Treatment of bone growth disorders
US10993983B2 (en) * 2016-03-18 2021-05-04 Trustees Of Tufts College Cyclic peptide epitopes and small-molecule mimics for inducing autophagy
US10774328B2 (en) * 2016-07-11 2020-09-15 University Of North Texas Health Science Center At Fort Worth Treatment for glaucoma and other eye diseases
EP3630963A1 (en) * 2017-05-30 2020-04-08 BioAxone BioSciences, Inc. C3 fusion protein and methods of making and using thereof

Similar Documents

Publication Publication Date Title
US7507529B2 (en) Oligonucleotides originating from sequences coding for the surface component of PTLV envelope proteins and their uses
JP7350485B2 (ja) ウイルスベクター効率を改善するための組成物及び方法
Simmonds et al. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1
Tsurutani et al. Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells
Wang et al. Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging
Aktar et al. Structural basis of genomic RNA (gRNA) dimerization and packaging determinants of mouse mammary tumor virus (MMTV)
Dube et al. The complete genomic sequence of a BLV strain from a Holstein cow from Argentina
Ansari et al. Interaction of YB-1 with human immunodeficiency virus type 1 Tat and TAR RNA modulates viral promoter activity
Möbius et al. A functionally selective synthetic mimic of the HIV‐1 co‐receptor CXCR4
Langley et al. Nucleotide sequence analysis of puma lentivirus (PLV-14): genomic organization and relationship to other lentiviruses
Weiss et al. Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia coli mediates dimerization and enhances reverse transcription of retroviral RNA
CN112442514B (zh) 慢病毒包装载体系统、慢病毒及其构建方法、试剂盒
Maury Regulation of equine infectious anemia virus expression
Zhuang et al. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways
Kono et al. Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5αs against human immunodeficiency virus type 2 infection
Vahlenkamp et al. A single amino acid substitution in the transmembrane envelope glycoprotein of feline immunodeficiency virus alters cellular tropism
Kurosu et al. Human immunodeficiency virus type 1 subtype C exhibits higher transactivation activity of Tat than subtypes B and E
Krishnan et al. Identification of a putative Gag binding site critical for feline immunodeficiency virus genomic RNA packaging
Vahlenkamp et al. Envelope gene sequences encoding variable regions 3 and 4 are involved in macrophage tropism of feline immunodeficiency virus
Dash et al. Exceptional molecular and coreceptor-requirement properties of molecular clones isolated from an Human Immunodeficiency Virus Type-1 subtype C infection
Guo et al. The R362A mutation at the C-terminus of CA inhibits packaging of human immunodeficiency virus type 1 RNA
Soezi et al. Toward the development of a single-round infection assay based on EGFP reporting for anti-HIV-1 drug discovery
Avidan et al. Expression and characterization of the integrase of bovine immunodeficiency virus
US7381817B2 (en) LTR region of MSRV-1 and the proteins it encodes, and probes and methods for detecting MSRV-1 retrovirus
US20110263460A1 (en) Compositions and methods for producing replication competent human immunodeficiency virus (hiv)